Discuss a project

UpperSolv™

Identifying the optimal bioavailability enhancement strategy for clinical success.

Speak to our experts
Batch of tablets in a pan coater, part of Upperton's tablet formulation development services

WHY UpperSolv™

Is your molecule held back by poor solubility?

UpperSolv™ is a rapid formulation screening platform designed to identify the most suitable bioavailability enhancement strategy using minimal API.

In as little as 5 grams of API, UpperSolv™ can evaluate multiple formulation development approaches and generate comparative data to support confident development decisions.

Benefits

  • Up to 6 formulation strategies evaluated
  • Minimal API requirements
  • Comparative PK data generated
  • Typical turnaround in 8-12 weeks
  • Supports progression towards clinical development

solving complex molecule challenges

When to use UpperSolv™

UpperSolv™ is ideally suited to:

  • Poorly soluble APIs
  • BCS Class II and IV molecules
  • New chemical entities
  • Molecules with uncertain formulation pathways
  • Development programmes with limited API availability
  • Sponsors evaluating multiple enabling technologies


What you receive

  • Comparative formulation performance data
  • PK assessment results
  • Lead formulation recommendation
  • Development pathway recommendation
  • Scalable strategy for clinical progression

whitepaper

Tackling Poor Bioavailability with Early Formulation Strategies.

Learn how early formulation screening helps identify successful bioavailability enhancement strategies before committing to costly development programmes.

Download Whitepaper

Find the right formulation strategy for you

Improved Bioavailability and Solubility in 12 Weeks.

UpperSolv™ helps identify the optimal bioavailability enhancement strategy before significant development investment is made.

Poor solubility is one of the most common barriers to successful drug development. While some molecules respond well to particle size reduction through micronisation, more challenging APIs often require a broader evaluation of enabling formulation approaches.

Using as little as 5g of API, UpperSolv™ applies a structured, data-driven screening process to rapidly assess multiple formulation strategies and identify the approach most likely to succeed in the clinic.

The platform:

  1. Assesses solubility across a range of solvents, co-solvents and excipients.
  2. Evaluates enabling technologies including lipid-based formulations, co-milling and spray-dried amorphous solid dispersions.
  3. Compares formulation performance through in vitro characterisation and stability studies.
  4. Generates comparative pharmacokinetic (PK) data to support confident development decisions.


The result is a science-led recommendation that reduces formulation risk, accelerates decision-making and identifies a scalable formulation strategy with the greatest potential for clinical and commercial success.

1

Solubility & Compatibility Screening

2

Shortlist Feasible Formulation Options

3

Assess Solubility in Multiple Vehicles and Excipients

4

Identification of Lead Formulation

Key Features of UpperSolv™

The UpperSolv™ Platform

  • Requires minimal API – typical 5 grams will support the testing of up to 6 formulations
  • Rapid turnaround – the entire study including generation of PK data will typically be complete in 8 weeks
  • Adaptive, tailored approach depending on the molecule and client objectives
  • Combined formulation and biopharmaceutical approach to selecting the most appropriate formulation strategy

The advantages of UpperSolv™

  • Rapid comparative PK assessment to support formulation strategy selection.
  • Rapid evaluation of a range of enabling technologies achieved with minimal drug.

UpperSolv™ provides the comparative data needed to select the formulation strategy most likely to succeed in clinical development.

Why use UpperSolv™

Minimal API Required

Typically only 5g needed

Multiple Strategies Compared

Reduce the risk of selecting the wrong pathway.

Comparative PK Assessment

Make evidence-based development decisions.

Designed for Clinical Success

Focus on scalable approaches suitable for future development.

Download Whitepaper

This field is for validation purposes and should be left unchanged.